← Eichor
Study identifier: NCT07239687 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Comparative Study of Eleveld and Schnider Pharmacokinetic Models for Target-Controlled Infusion of Propofol in Sedation of Mechanically Ventilated ICU Patients

Condition: Intensive Care Unit Sedation · Sedation · Target Controlled Infusion of Propofol  ·  Sponsor: Hacettepe University

PhaseN/A
Planned participants84
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This prospective observational study aims to compare the clinical performance of two target-controlled infusion (TCI) models, Eleveld and Schnider, for propofol sedation in mechanically ventilated intensive care unit (ICU) patients. The study evaluates sedation depth, hemodynamic stability, and recovery profiles using the Bispectral Index (BIS) and Riker Sedation-Agitation Scale. Secondary outcomes include awakening time, total propofol dose, and incidence of delirium after sedation withdrawal. The findings may help identify the most reliable pharmacokinetic model for safe and effective ICU sedation.

This description comes directly from the study's public registry record.

Talk to the study team

DUYGU OZDEMIR SIMSEK, MD  ·  +905372916432  ·  duyguozdemir94@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Hacettepe UniversityAnkara, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07239687